Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: A prospective study of 3-year outcomes

International Clinical Psychopharmacology

Volumn 26, Issue 3, 2011, Pages 146-150

  Malempati, Rao Narasimha ^a,b   Bond, David J ^c   Kunz, Mauricio ^c   Malemati, Chaitanya ^b   Cheng, Amy ^b   Yatham, Lakshmi N ^c  

^a Hotel Dieu Grace Hospital Windsor   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

bipolar disorder; maintenance treatment; psychosis; risperidone long acting injectable

Indexed keywords

BENZATROPINE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; PHENYLTOLOXAMINE CITRATE; RISPERIDONE; RISPERIDONE LONG ACTING INJECTABLE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITALIZATION; HUMAN; MALE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; RELAPSE; SIDE EFFECT; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954706241     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328343ba60     Document Type: Article

References (14)

1. Azorin JM, Kaladjian A, Adida M, Hantouche E, Hameg A, Lancrenon S, Akiskal HS (2008). Toward the delineation of mania subtypes in the French National EPIMAN-II Mille Cohort: comparisons with prior cluster analytic investigations. Eur Arch Psychiatry Clin Neurosci 258:497-504.
2. Bond DJ, Pratoomsri W, Yatham LN (2007). Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr Scand 116: 3-16. (Pubitemid 47231064)
3. Conus P, Abdel-Baki A, Harrigan S, Lambert M, McGorry PD (2004). Schneiderian first rank symptoms predict poor outcome within first episode manic psychosis. J Affect Disord 81:259-268. (Pubitemid 39141915)
4. Coryell W, Leon AC, Turvey C, Akiskal HS, Mueller T, Endicott J (2001). The significance of psychotic features in manic episodes: a report from the NIMH collaborative study. J Affect Disord 67:79-88. (Pubitemid 34183338)
5. Goodwin FK, Jameson KR (2007). Manic depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York: Oxford University Press.
6. Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK (2007). Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:1219-1223. (Pubitemid 47081306)
7. Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, et al. (2009). A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 11:827-839.
8. Malempati RN, Bond DJ, Yatham LN (2008). Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int Clin Psychopharmacol 23:88-94. (Pubitemid 351317281)
9. Medori R, Braunig P, Sacchetti E (2005). Bipolar diorder: 6-months efficacy of risperidone injectable. World J Biol Psychiatry 6 (Suppl 1):192-193.
10. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC (2007). Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64:543-552. (Pubitemid 46718287)
11. Murray CJL, Lopez AD, editors (1996). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press.
12. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V (2010). Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 68:156-162.
13. Savas HA, Yumru M, Ozen ME (2006). Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol 26:530-531. (Pubitemid 44401480)
14. Yatham LN, Fallu A, Binder CE (2007). A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand 116:50-56. (Pubitemid 47231068)